Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
BACKGROUND
Surface enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) analysis on serum samples was reported to be able to detect colorectal cancer (CRC) from normal or control patients. We carried out a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify CRC.


METHODS
A retrospective cohort of 338 serum samples including 154 CRCs, 67 control cancers and 117 non-cancerous conditions was profiled using SELDI-TOF-MS.


RESULTS
No CRC "specific" classifier was found. However, a classifier consisting of two protein peaks separates cancer from non-cancerous conditions with high accuracy.


CONCLUSIONS
In this study, the SELDI-TOF-MS-based protein expression profiling approach did not perform to identify CRC. However, this technique is promising in distinguishing patients with cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after treatment.
Wang
Qi
Q
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, PR China. wangki2004@126.com
Shen
Jing
J
Li
Zhen-fu
ZF
Jie
Jian-zheng
JZ
Wang
Wen-yue
WY
Wang
Jin
J
Zhang
Zhong-tao
ZT
Li
Zhi-xia
ZX
Yan
Li
L
Gu
Jin
J
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods*; D012189:Retrospective Studies; D044967:Serum / Q000737:chemistry*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*
D014408:Biomarkers, Tumor
Clin Chem. 2002 Aug;48(8):1296-304
12142387
Ann Intern Med. 2008 Oct 7;149(7):441-50, W81
18838724
Clin Chem. 2007 Apr;53(4):645-56
17303688
Zhonghua Liu Xing Bing Xue Za Zhi. 2005 May;26(5):366-9
16053766
Cancer Res. 2002 Jul 1;62(13):3609-14
12097261
Eur J Cancer. 2003 Apr;39(6):718-27
12651195
J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61
11459866
Cancer Inform. 2005;1:86-97
19305634
Lancet. 1996 Nov 30;348(9040):1467-71
8942774
Clin Chem. 2008 Jan;54(1):44-52
17981926
Cancer Res. 2005 Nov 15;65(22):10613-22
16288055
J Natl Cancer Inst. 2004 Mar 3;96(5):353-6
14996856
Clin Chem. 2008 Jan;54(1):53-60
18024530
Ann Thorac Surg. 2007 Aug;84(2):384-92; discussion 392
17643604
Clin Chem. 2005 Jan;51(1):102-12
15613711
Br J Cancer. 2006 Jun 19;94(12):1898-905
16755300
Am J Gastroenterol. 2008 Nov;103(11):2862-70
18759824
J Urol. 2003 Aug;170(2 Pt 1):442-6
12853795
BMC Cancer. 2005 Jan 19;5:8
15656915
CA Cancer J Clin. 2000 Jan-Feb;50(1):34-49
10735014
Br J Cancer. 2006 Jan 30;94(2):287-92
16404431
J Natl Cancer Inst. 2005 Feb 16;97(4):315-9
15713968
Clin Chem. 2003 May;49(5):752-60
12709366
Lancet. 2002 Feb 16;359(9306):572-7
11867112
J Urol. 2005 Oct;174(4 Pt 1):1213-7
16145372
Clin Chem. 2001 Apr;47(4):624-30
11274010
Nat Rev Cancer. 2005 Feb;5(2):142-9
15685197
Am J Pathol. 2001 Apr;158(4):1491-502
11290567
Cancer Invest. 2006 Dec;24(8):747-53
17162557
Clin Cancer Res. 2004 Dec 15;10(24):8380-5
15623616